AR073599A1 - Compuestos heterociclicos como ligandos de receptores de canabinoides - Google Patents
Compuestos heterociclicos como ligandos de receptores de canabinoidesInfo
- Publication number
- AR073599A1 AR073599A1 ARP090103558A ARP090103558A AR073599A1 AR 073599 A1 AR073599 A1 AR 073599A1 AR P090103558 A ARP090103558 A AR P090103558A AR P090103558 A ARP090103558 A AR P090103558A AR 073599 A1 AR073599 A1 AR 073599A1
- Authority
- AR
- Argentina
- Prior art keywords
- cr1cr1d
- haloalkyl
- alkyl
- independently
- instance
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
Se divulgan asimismo composiciones que comprenden dichos compuestos y métodos para el tratamiento de condiciones y trastornos usando dichos compuesto y composiciones. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1), o una sal, solvato, prodroga, o sal de prodroga farmacéuticamente aceptable o combinacion de los mismos donde X4 es O, S, S(O), S(O)2, o N(Rbx); donde Rbx es hidrogeno, alquilo, haloalquilo, alcoxialquilo, -C(O)O(alquilo), cicloalquilo monocíclico, -(CR1cR1d)q3-(cicloalquilo monocíclico). o haloalcoxialquilo; y A1 es -G1a-G1b, -(CR1aR1b)q1-G1c, -(CR1aR1b)q1-A2, -(CR1gR1h)q2-A4, -N(Rb)C(O)Ra, -N(Rb)C(O)ORd, -N(Rb)C(O)N(Rb)(Rc), -N(Rb)(Rc), o -N=C(Rp)Rq); o X4 y A1 juntos son N=N(Rcx); A2 es -C(O)Ra, -S(O)2Rd, -SRd, -C(O)ORa, C(O)N(Rb)(Rc), -C(S)N(Rb)(Rc), -S(O)2N(Rb)(Rc), -C(=NORf)Ra, -CN, -N(Rc)C(O)Ra, -N(Rc)C(O)ORd, -N(Rc)S(O)2Rd, -N(Rc)C(O)N(Rb)(Rc), -N(Rc)S(O)2N(Rb)(Rc), -ORm, o -N(Rb)(Rn); A3 -C(O)Rh, -S(O)2Re, -C(O)N(Rh)2, C(S)N(Rh)2, -S(O)2N(Rh)2, -C(=NORh)Rh, -N(Rh)C(O)Rh, -N(Rh)C(O)ORe, -N(Rh)S(O)2Re, -N(Rh)C(O)N(Rh)2, -N(Rh)S(O)2N(Rh)2, -CN, -ORh, o -N(Rh)2; A4 es cicloalquilo, alcoxi, haloalcoxi, o N(R1m)2 donde cada instancia de R1m es en forma independiente hidrogeno o alquilo; cada instancia de Ra y Rc, es en forma independiente hidrogeno, alquilo, haloalquilo, -(CR1aR1b)q3-A3, G1d, o -(CR1aR1b)q3-G1d; Rb, en cada instancia, es en forma independiente hidrogeno, alquilo, haloalquilo, alcoxialquilo, cicloalquilo monocíclico, -(CR1cR1d)q3-(cicloalquilo monocíclico), o haloalcoxialquilo; Rd en cada instancia, es en forma independiente alquilo. haloalquilo, -(CR1aR1b)q3-A3, G1d, o -(CR1aR1b)q3-G1d; Rcx es alquilo, haloalquilo, -(CR1aR1b)q3-A3, G1d, o -(CR1aR1b)q3-G1d; Rm es H, -(CR1aR1b)q3-A3, G1d, o -(CR1aR1b)q3-G1d; Rn es haloalquilo, -(CR1aR1b)q3-A3, G1d, o -(CR1aR1b)q3-G1d; Rp es H, alquilo, haloalquilo, -(CR1aR1b)q3-A3, -C(O)ORd, -C(O)Rd, G1d, o -(CR1aR1b)q3-G1d; Rq es H, alquilo, haloalquilo, -N(Rb)(Rc), -(CR1aR1b)q3-A3, G1d, o -(CR1aR1b)q3-G1d; o Rp y Rq, junto con el átomo de carbono al cual están unidos, forman un anillo monocíclico de 5, 6, 7 u 8 miembros, opcionalmente sustituido con 1, 2, 3, 4, o 5 sustituyentes seleccionados en forma independiente entre el grupo que consiste en oxo, alquilo, haloalquilo, y halogeno; A5 representa la formula (a), (b), (c), (d), o (e); G1a y G1b son en forma independiente cicloalquilo, cicloalquenilo, heterociclo, arilo, o heteroarilo; G1c es cicloalquenilo, heterociclo, arilo, o heteroarilo; el anillo representado por G1a está opcionalmente sustituido con 1, 2, 3, 4, o 5 sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, alquenilo, alquinilo, halogeno, haloalquilo, =N-CN, =N-ORf, -CN, oxo, -ORf, -OC(O)Rf, -OC(O)N(Rf)2, -S(O)2Re, -S(O)2N(Rf)2, -C(O)Rf, -C(O)ORf, -C(O)N(Rf)2, -N(Rf)2, -N(Rf)C(O)Rf, N(Rf)S(O)2Re. -N(Rf)C(O)O(Re), N(Rf)C(O) N(Rf)2, -(CR1cR1d)q3-ORf, -(CR1cR1d)q3-OC(O)Rf, -(CR1cR1d)q3-OC(O)N(Rf)2, -(CR1cR1d)q3-S(O)2Re, -(CR1cR1d)q3-S(O)2N(Rf)2, -(CR1cR1d)q3-C(O)Rf, -(CR1cR1d)q3-C(O)ORf, -(CR1cR1d)q3-C(O)N(Rf)2, -(CR1cR1d)q3-N(Rf)2, -(CR1cR1d)q3-N(Rf)C(O)Rf, -(CR1cR1d)q3-N(Rf)S(O)2Re, -(CR1cR1d)q3-N(Rf)C(O)O(Re), -(CR1cR1d)q3-N(Rf)C(O)N(Rf)2, y -(CR1cR1d)q3-CN; los anillos representados por G1b, G1c y el cicloalquilo de A4 están opcionalmente sustituidos en cada caso con 1, 2, 3, 4, o 5 sustituyentes seleccionados en forma independiente entre el grupo que consiste en G1d, alquilo, alquenilo, alquinilo, halogeno, haloalquilo, =N-CN, =N-ORf, -CN, oxo, -ORf, -OC(O)Rf, -OC(O)N(Rf)2, -S(O)2Re, -S(O)2N(Rf)2, -C(O)Rf, -C(O)ORf, -C(O)N(Rf)2, -N(Rf)2, -N(Rf)C(O)Rf, N(Rf)S(O)2Re. -N(Rf)C(O)O(Re), N(Rf)C(O)N(Rf)2, -(CR1cR1d)q3-G1d, -(CR1cR1d)q3-ORf, -(CR1cR1d)q3-OC(O)Rf, -(CR1cR1d)q3-OC(O)N(Rf)2, -(CR1cR1d)q3-S(O)2Re, -(CR1cR1d)q3-S(O)2N(Rf)2, -(CR1cR1d)q3-C(O)Rf, -(CR1cR1d)q3-C(O)ORf, -(CR1cR1d)q3-C(O)N(Rf)2, -(CR1cR1d)q3-N(Rf)2, -(CR1cR1d)q3-N(Rf)C(O)Rf, -(CR1cR1d)q3-N(Rf)S(O)2Re, -(CR1cR1d)q3-N(Rf)C(O)O(Re), -(CR1cR1d)q3-N(Rf)C(O)N(Rf)2, y -(CR1cR1d)q3-CN; G1d, en cada instancia, es en forma independiente un heterociclo monocíclico, un heteroarilo monocíclico, un fenilo, un cicloalquilo monocíclico, o un cicloalquenilo monocíclico; donde G1d está opcionalmente sustituido con 1, 2, 3, o 4 sustituyentes seleccionados en forma independiente entre el grupo que consiste en -N(Rh)2, -CN, oxo, alquilo, haloalquilo, alcoxi, haloalcoxi, halogeno, y OH; Re, en cada instancia, es en forma independiente alquilo C1-4, haloalquilo C1-4, cicloalquilo monocíclico, heterociclo monocíclico, o -(CR1cR1d)q3-(cicloalquilo monocíclico); Rf, en cada instancia, es en forma independiente hidrogeno, alquilo C1-4, haloalquilo C1-4, -(CR1cR1d)q3-ORh, heterociclo monocíclico, cicloalquilo monocíclico, o -(CR1cR1d)q3-(cicloalquilo monocíclico); Rh en cada instancia, es en forma independiente hidrogeno, alquilo C1-4, haloalquilo C1-4, cicloalquilo monocíclico, o -(CR1cR1d)q3-(cicloalquilo monocíclico); R21, R22, R23, R24, y R25 es en forma independiente alquilo, alquenilo, alquinilo, haloalquilo, -(CR2aR2b)q4-OH, -(CR2aR2b)q4-O-alquilo, -(CR2aR2b)q4-O-haloalquilo, -(CR2aR2b)q4-O-G2a, -(CR2aR2b)q4-O-(CR2cR2d)q3-G2a, -(CR2aR2b)q5-C(O)Ra, -(CR2aR2b)q5-C(=NORf)Ra, -(CR2aR2b)q5-SO2-Rd, -(CR2aR2b)q5-G2b, -(CR2aR2b)q5-C(O)N(Rb)(Rc), o -(CR2aR2b)q5-CN; cada instancia de G2a es en forma independiente cicloalquilo, heterociclo, arilo, o heteroarilo; G2b es un anillo monocíclico seleccionado entre el grupo que consiste en cicloalquilo, cicloalquenilo, tienilo, fenilo, furanilo, oxazolilo, isoxazolilo, oxadiazolilo, y heterociclo; donde el heterociclo contiene 0 o 1 doble enlace, 1 o 2 oxígenos, y 0 o 1 nitrogeno como átomos del anillo, dos átomos no adyacentes de dicho anillo heterociclo pueden estar opcionalmente unidos por medio de un puente alquenileno de 2, 3, o 4 átomos de carbono, u opcionalmente unidos por un puente alquileno de 1, 2, 3, o 4 átomos de carbono; cada anillo G2b está opcionalmente fusionado con un anillo monocíclico seleccionado entre el grupo que consiste en benzo, cicloalquilo, cicloalquenilo, heterociclo y heteroarilo; cada instancia de G2a y G2b en forma independiente no está sustituida o está sustituida con 1, 2, 3, 4, 5, o 6 sustituyentes seleccionados en forma independiente entre el grupo que consiste en oxo, alquilo, halogeno, -OH. alcoxi, haloalcoxi. y haloalquilo; X1 es O o S; X2 es O, S, o N(R10) donde R10 es alquilo, alcoxialquilo, haloalcoxialquilo, o haloalquilo; X3 es O o S; R3, R4, R5, R6, R7, R8, R9. R11, y R12 es en forma independiente G3, hidrogeno, alquilo, alquenilo, alquinilo, -NO2, -CN, halogeno, -ORh, -N(Rh)2, -C(O)Rh, -C(OO(Rh), haloalquilo, -(CR3aR3b)q6-ORh, -(CR3aR3b)q6-N(Rh)2, -(CR3aR3b)q6-C(O)Rh, o -(CR3aR3b)q6-C(O)O(Rh); R13 y R14 es en forma independiente G3, hidrogeno, alquilo, haloalquilo, o -(CR3aR3b)q6-Orh; o R13 y R14 tomados junto con el átomo de carbono al cual están unidos forman un anillo heterociclo monocíclico o un anillo cicloalquilo monocíclico, donde cada uno de los cuales en forma independiente no está sustituido o está sustituido con 1, 2, 3, o 4 sustituyentes seleccionados entre el grupo que consiste en alquilo, OH, alcoxi, haloalcoxi, haloalquilo, y oxo; R15 y R16 es en forma independiente G3, hidrogeno, alquilo. haloalquilo, o -(CR3aR3b)q6-Orh; o R15 y R16 tomados junto con el átomo de carbono al cual están unidos forman un anillo cicloalquilo monocíclico o un anillo heterociclo monocíclico; donde cada uno de los cuales en forma independiente no está sustituido o está sustituido con 1, 2, 3, o 4 sustituyentes seleccionados entre el grupo que consiste en alquilo, OH, alcoxi, haloalcoxi, haloalquilo, y oxo; G3, en cada instancia, es en forma independiente cicloalquilo, cicloalquenilo, arilo, heterociclo, o heteroarilo, donde cada G3 en forma independiente no está sustituida o está sustituida con 1, 2, 3 o 4 sustituyentes seleccionados entre el grupo que consiste en alquilo C1-4, alquenilo C2-4, alquinilo C2-4, halogeno, haloalquilo C1-4, =N-CN, =N-ORh, -CN, oxo, -ORh, -OC(O)Rh, -OC(O)N(Rh)2, -S(O)2Re, -S(O)2N(Rh)2, -C(O)Rh, -C(O)ORh, -C(O)N(Rh)2, -N(Rh)2, -N(Rh)C(O)Rh, -N(Rh)S(O)2Re, -N(Rh)C(O)O(Re), y -N(Rh)C(O)N(Rh)2; R1a, en cada instancia, es en forma independiente hidrogeno, halogeno, alquilo C1-4, o haloalquilo C1-4; R1b, en cada instancia, es en forma independiente hidrogeno, halogeno, alquilo C1-4, alquenilo C2-4, haloalquilo C1-4, -ORh, -N(Rh)2, -N(Rh)C(O)Rh, -N(Rh)C(O)ORe, o -N(Rh)S(O)2Re; R1g, en cada instancia, es en forma independiente hidrogeno, halogeno, alquilo C1-4, haloalquilo C1-4, -ORh, -N(Rh)2, -N(Rh)C(O)Rh, -N(Rh)C(O)ORe, o -N(Rh)S(O)2Re; con la condicion de que al menos una instancia de R1g es halogeno, haloalquilo C1-4, -ORh, -N(Rh)2, -N(Rh)C(O)Rh, -N(Rh)C(O)ORe, o - N(Rh)S(O)2Re; R1h, en cada instancia, es en forma independiente hidrogeno, halogeno, alquilo C1-4, o haloalquilo C1-4; R1c, R1d, R2a, R2b, R2c, R2d, R3a, y R3b, en cada instancia, es en forma independiente hidrogeno, halogeno, alquilo C1-4, o haloalquilo C1-4; Rx en cada instancia, es en forma independiente G1d, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, halogeno, haloalquilo C1-4, NO2, -CN, -ORf, -OC(O)Rf, -OC(O)N(Rf)2, -S(O)2Re, -S(O)2N(Rf)2, -C(O)Rf, -C(O)ORf, -C(O)N(Rf)2, -N(Rf)2, -N(Rf)C(O)Rf, N(Rf)S(O)2Re. -N(Rf)C(O)O(Re), N(Rf)C(O) N(Rf)2, -(CR1cR1d)q3-ORf, -(CR1cR1d)q3-OC(O)Rf, -(CR1cR1d)q3-OC(O)N(Rf)2, -(CR1cR1d)q3-S(O)2Re, -(CR1cR1d)q3-S(O)2N(Rf)2, -(CR1cR1d)q3-C(O)Rf, -(CR1cR1d)q3-C(O)ORf, -(CR1cR1d)q3-C(O)N(Rf)2, -(CR1cR1d)q3-N(Rf)2, -(CR1cR1d)q3-N(Rf)C(O)Rf, -(CR1cR1d)q3-N(Rf)S(O)2Re, -(CR1cR1d)q3-N(Rf)C(O)O(Re), -(CR1cR1d)q3-N(Rf)C(O)N(Rf)2, o -(CR1cR1d)q3-CN; q1 en cada instancia, es en forma independiente 1. 2, 3, o 4; q2 y q4, en cada instancia, son en forma independiente 2, 3. 4, o 5; q3, en cada instancia, es 1, 2 o 3; q5 y q6, en cada instancia, son en forma independiente 1, 2, 3, 4, 5, o 6, z es 0, 1, 2, 3, o 4; y el cicloalquilo monocíclico
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9737808P | 2008-09-16 | 2008-09-16 | |
US22420009P | 2009-07-09 | 2009-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR073599A1 true AR073599A1 (es) | 2010-11-17 |
Family
ID=41210849
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090103558A AR073599A1 (es) | 2008-09-16 | 2009-09-16 | Compuestos heterociclicos como ligandos de receptores de canabinoides |
ARP100102555A AR077664A2 (es) | 2008-09-16 | 2010-07-14 | Compuestos como ligandos de receptores de canabinoides |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100102555A AR077664A2 (es) | 2008-09-16 | 2010-07-14 | Compuestos como ligandos de receptores de canabinoides |
Country Status (23)
Country | Link |
---|---|
US (2) | US8188135B2 (es) |
EP (3) | EP2896615A1 (es) |
JP (1) | JP2012502917A (es) |
KR (1) | KR20110061619A (es) |
CN (1) | CN102216277A (es) |
AR (2) | AR073599A1 (es) |
AU (1) | AU2009293319A1 (es) |
BR (1) | BRPI0919135A2 (es) |
CA (1) | CA2737199A1 (es) |
CL (1) | CL2011000544A1 (es) |
CO (1) | CO6361998A2 (es) |
DO (1) | DOP2011000081A (es) |
EC (1) | ECSP11010974A (es) |
ES (1) | ES2556752T3 (es) |
IL (1) | IL211406A0 (es) |
MX (1) | MX2011002811A (es) |
PA (1) | PA8842501A1 (es) |
PE (1) | PE20110804A1 (es) |
RU (1) | RU2011115087A (es) |
TW (1) | TW201016692A (es) |
UY (1) | UY32125A (es) |
WO (1) | WO2010033543A2 (es) |
ZA (1) | ZA201101590B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8841334B2 (en) * | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
WO2007140385A2 (en) * | 2006-05-31 | 2007-12-06 | Abbott Laboratories | Thiazole compounds as cannabinoid receptor ligands and uses thereof |
CA2647598A1 (en) * | 2006-05-31 | 2007-12-06 | Abbott Laboratories | Compounds as cannabinoid receptor ligands and uses thereof |
CN101765594A (zh) | 2007-03-28 | 2010-06-30 | 雅培制药有限公司 | 作为大麻素受体配体的1,3-噻唑-2(3h)-亚基化合物 |
US7872033B2 (en) * | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
WO2008144360A1 (en) * | 2007-05-18 | 2008-11-27 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands |
US9193713B2 (en) * | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
MX2010010023A (es) | 2008-03-11 | 2010-11-30 | Abbott Lab | Compuestos novedosos como ligandos receptores de canabinoides. |
US8846730B2 (en) * | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
CN102216277A (zh) * | 2008-09-16 | 2011-10-12 | 雅培制药有限公司 | 作为大麻素受体配体的被取代的苯甲酰胺 |
PA8854001A1 (es) * | 2008-12-16 | 2010-07-27 | Abbott Lab | Compuestos novedosos como ligandos de receptores de canabinoides |
ES2542234T3 (es) * | 2009-03-27 | 2015-08-03 | Abbvie Inc. | Compuestos como ligandos de receptores cannabinoides |
WO2011159785A1 (en) | 2010-06-15 | 2011-12-22 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands |
CN103396376B (zh) * | 2013-07-31 | 2016-08-10 | 杨文茂 | 一种抗菌抗癌活性化合物 |
ES2637029T3 (es) * | 2014-05-19 | 2017-10-10 | Syngenta Participations Ag | Derivados amídicos activos como insecticidas con grupos piridino o fenilo sustituidos con azufre |
EP3212241B1 (en) * | 2014-10-27 | 2019-05-08 | F. Hoffmann-La Roche AG | Radiolabeled cannabinoid receptor 2 ligand |
CN106749078B (zh) * | 2015-11-23 | 2019-01-04 | 中国科学院大连化学物理研究所 | 一种2-亚胺基恶唑的合成方法 |
Family Cites Families (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1522361A1 (de) | 1966-03-08 | 1969-07-24 | Agfa Gevaert Ag | Sensibilisierung lichtempfindlicher Polymerer |
US3557142A (en) * | 1968-02-20 | 1971-01-19 | Sterling Drug Inc | 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters |
DE1772867A1 (de) | 1968-07-15 | 1971-06-16 | Agfa Gevaert Ag | Sensibilisierung von Schichten aus lichtvernetzbaren Polymeren |
JPS5089367A (es) | 1973-12-14 | 1975-07-17 | ||
JPS57171986A (en) | 1981-04-14 | 1982-10-22 | Taiho Yakuhin Kogyo Kk | Heterocylic ring compound containing sulfur |
DE3333450A1 (de) * | 1983-09-16 | 1985-04-11 | Hoechst Ag, 6230 Frankfurt | Trihalogenmethylgruppen enthaltende carbonylmethylenheterocyclen, verfahren zu ihrer herstellung und lichtempfindliches gemisch, das diese verbindungen enthaelt |
US4885295A (en) * | 1984-08-06 | 1989-12-05 | Sterling Drug Inc. | Method of use of 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indoles |
US4978664A (en) * | 1984-08-06 | 1990-12-18 | Sterling Drug Inc. | 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indole pharmaceutical compositions |
DE3533331A1 (de) | 1985-09-18 | 1987-03-26 | Heumann Ludwig & Co Gmbh | Pyridothiazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
DE3807381A1 (de) * | 1988-03-07 | 1989-09-21 | Hoechst Ag | 4,6-bis-trichlormethyl-s-triazin-2-ylgruppen enthaltende heterocyclische verbindungen, verfahren zu ihrer herstellung und lichtempfindliches gemisch, das diese verbindung enthaelt |
TW205041B (es) | 1989-08-07 | 1993-05-01 | Fujisawa Pharmaceutical Co | |
DE4021439A1 (de) * | 1989-12-14 | 1991-06-20 | Bayer Ag | 2-iminopyridin-derivate |
US6559186B1 (en) * | 1990-02-26 | 2003-05-06 | Arc 1, Inc. | Compositions and methods of treatment of sympathetically maintained pain |
US4973587A (en) * | 1990-03-08 | 1990-11-27 | Sterling Drug Inc. | 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method |
US5013837A (en) * | 1990-03-08 | 1991-05-07 | Sterling Drug Inc. | 3-Arylcarbonyl-1H-indole-containing compounds |
WO1992015564A1 (en) | 1991-03-11 | 1992-09-17 | Nippon Soda Co., Ltd. | Novel heterocyclic compound |
DE69325018T2 (de) * | 1992-03-03 | 1999-09-16 | Idemitsu Kosan Co | Pyrazolderivate |
EP0568096B1 (en) | 1992-04-30 | 1998-07-29 | Hodogaya Chemical Co., Ltd. | Benzothiazole derivative and agricultural and horticultural fingicide composition containing the same |
US5654322A (en) * | 1992-08-11 | 1997-08-05 | Wakunaga Seiyaku Kabushiki Kaisha | Biphenylmethane derivatives and pharmaceuticals containing the same |
WO1994022821A1 (en) * | 1993-04-05 | 1994-10-13 | Fujisawa Pharmaceutical Co., Ltd. | Indole derivatives as testosterone 5 alpha-reductase inhibitors |
US5395836A (en) | 1993-04-07 | 1995-03-07 | Kyowa Hakko Kogyo Co., Ltd. | 8-tricycloalkyl xanthine derivatives |
JPH06345736A (ja) | 1993-06-14 | 1994-12-20 | Tokuyama Soda Co Ltd | ウレタン化合物を製造する方法 |
MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
CA2189573A1 (en) | 1994-05-17 | 1995-11-23 | Ronald E. Hackler | N-(5-isothiazolyl)amide pesticides |
ES2185707T5 (es) | 1994-07-08 | 2007-05-01 | Ev3 Inc. | Dispositivo de filtraje intravascular. |
FR2735774B1 (fr) | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
US6277985B1 (en) | 1995-09-15 | 2001-08-21 | Pharmacia & Upjohn Company | Aminoaryl oxazolidinone N-oxides |
US20030220234A1 (en) * | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
US6323214B1 (en) * | 1997-10-29 | 2001-11-27 | Medco Research, Inc | Allosteric adenosine receptor modulators |
US6358992B1 (en) * | 1998-11-25 | 2002-03-19 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with indole derivatives |
IL145962A0 (en) | 1999-04-20 | 2002-07-25 | Syngenta Ltd | Pesticidal indazole or benzotriazole derivatives |
DE19928033A1 (de) | 1999-06-18 | 2000-12-21 | Basf Ag | Verwendung von cyclischen Enaminen als Lichtschutzmittel |
FR2796643B1 (fr) | 1999-07-22 | 2005-04-29 | Sod Conseils Rech Applic | Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique |
GB9918037D0 (en) * | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
WO2001016138A1 (en) | 1999-08-27 | 2001-03-08 | Abbott Laboratories | Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors |
CA2384757A1 (en) | 1999-09-14 | 2001-03-22 | Shionogi & Co., Ltd. | 2-imino-1,3-thiazine derivatives |
WO2001028557A1 (en) | 1999-10-18 | 2001-04-26 | University Of Connecticut | Cannabimimetic indole derivatives |
GB0002032D0 (en) | 2000-01-28 | 2000-03-22 | Zeneca Ltd | Chemical compounds |
GB0002034D0 (en) | 2000-01-28 | 2000-03-22 | Zeneca Ltd | Chemical compounds |
GB0006289D0 (en) * | 2000-03-15 | 2000-05-03 | Smithkline Beecham Plc | New use |
GB0010437D0 (en) | 2000-04-28 | 2000-06-14 | Darwin Discovery Ltd | Process |
DK1300401T3 (da) | 2000-06-30 | 2010-02-01 | Dainippon Sumitomo Pharma Co | Thiazolderivater til anvendelse som antiinflammatoriske midler |
US6369052B1 (en) * | 2000-08-07 | 2002-04-09 | Georgetown University | Combination of huperzine and nicotinic compounds as a neuroprotective agent |
FR2816938B1 (fr) * | 2000-11-22 | 2003-01-03 | Sanofi Synthelabo | Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant |
US7173027B2 (en) | 2001-01-29 | 2007-02-06 | University Of Connecticut | Receptor selective cannabimimetic aminoalkylindoles |
AU2002310441A1 (en) | 2001-06-14 | 2003-01-02 | The Regents Of The University Of California | A novel signaling pathway for the production of inflammatory pain and neuropathy |
US7949668B2 (en) * | 2001-08-20 | 2011-05-24 | Pardalis, Inc. | Common point authoring system for the complex sharing of hierarchically authored data objects in a distribution chain |
WO2003029199A1 (fr) * | 2001-09-28 | 2003-04-10 | Takeda Chemical Industries, Ltd. | Derives de benzene et procede de preparation et d'utilisation associe |
AU2002363174B2 (en) * | 2001-11-01 | 2008-09-25 | Janssen Pharmaceutica N.V. | Amide derivatives as glycogen synthase kinase 3-beta inhibitors |
US6727247B2 (en) | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
WO2003097605A1 (en) * | 2002-05-16 | 2003-11-27 | Bayer Cropscience Gmbh | Pesticidal pyridinecarboxamide derivatives |
JP3902523B2 (ja) * | 2002-08-05 | 2007-04-11 | 富士フイルム株式会社 | 光情報記録媒体および情報記録方法 |
US20040077617A1 (en) * | 2002-10-22 | 2004-04-22 | Bennani Youssef L. | Fused cycloalkyl amides and acids and their therapeutic applications |
FR2847899B1 (fr) | 2002-11-29 | 2006-04-28 | Sanofi Synthelabo | Derives d'indole-3-carboxamide, leur preparation et leur application en therapeutique |
US7390670B2 (en) * | 2003-02-20 | 2008-06-24 | Lumigen, Inc. | Signalling compounds and methods for detecting hydrogen peroxide |
US20040259887A1 (en) | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US20070105908A1 (en) | 2003-06-27 | 2007-05-10 | Dainippon Sumitomo Pharma Co., Ltd. | Thiazolimine compound and oxazolimine compound |
US6964237B2 (en) | 2003-06-30 | 2005-11-15 | Mark P. Hepp | Grate block for a refuse incineration grate |
EP1670804A2 (en) | 2003-09-10 | 2006-06-21 | GPC Biotech AG | Heterobicyclic compounds as pharmaceutically active agents |
AU2004299198A1 (en) | 2003-12-08 | 2005-06-30 | F. Hoffmann-La Roche Ag | Novel thiazole derivates |
GB0402357D0 (en) | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
US7307163B2 (en) | 2004-04-19 | 2007-12-11 | Symed Labs Limited | Process for the preparation of linezolid and related compounds |
SE0401345D0 (sv) | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds: Pyridine as scaffold |
SE0401342D0 (sv) | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds |
EP1768967B1 (en) | 2004-07-20 | 2009-04-22 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
US7511013B2 (en) | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
WO2006051704A1 (ja) | 2004-11-15 | 2006-05-18 | Taisho Pharmaceutical Co., Ltd. | イミン化合物 |
EP1833824B1 (en) * | 2004-12-21 | 2016-08-03 | AbbVie Inc. | 3-cycloalkylcarbonyl indoles as cannabinoid receptor ligands |
FR2880023B1 (fr) | 2004-12-23 | 2007-02-23 | Sanofi Aventis Sa | Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique |
US7759337B2 (en) * | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
TW200700387A (en) | 2005-03-21 | 2007-01-01 | Akzo Nobel Nv | 1-benzylindole-2-carboxamide derivatives |
US7674912B2 (en) * | 2005-04-25 | 2010-03-09 | H. Lundbeck A/S | Pro-drugs of N-thiazol-2-yl-benzamide derivatives |
US20070155738A1 (en) * | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
TW200716636A (en) * | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
US7514068B2 (en) * | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
WO2007046550A1 (en) * | 2005-10-21 | 2007-04-26 | Mitsubishi Tanabe Pharma Corporation | Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity |
TW200804338A (en) | 2005-11-24 | 2008-01-16 | Astrazeneca Ab | New compounds |
KR100778673B1 (ko) | 2005-12-26 | 2007-11-22 | 주식회사 포스코 | 용철 제조 장치 |
US8841334B2 (en) * | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
WO2007140385A2 (en) | 2006-05-31 | 2007-12-06 | Abbott Laboratories | Thiazole compounds as cannabinoid receptor ligands and uses thereof |
CA2647598A1 (en) | 2006-05-31 | 2007-12-06 | Abbott Laboratories | Compounds as cannabinoid receptor ligands and uses thereof |
TW200813000A (en) * | 2006-06-27 | 2008-03-16 | Abbott Lab | Thiazoline and oxazoline derivatives and their methods of use |
EP2054393A1 (en) | 2006-07-28 | 2009-05-06 | Synthon B.V. | Crystalline erlotinib |
WO2008028093A1 (en) * | 2006-08-31 | 2008-03-06 | Abbott Laboratories | Compounds as cb2 cannabinoid receptor ligands |
US7985768B2 (en) * | 2006-08-31 | 2011-07-26 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
WO2008063781A2 (en) | 2006-10-12 | 2008-05-29 | Abbott Laboratories | Chemical compounds as cannabinoid receptor ligands |
US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
US7793912B2 (en) * | 2006-11-08 | 2010-09-14 | Denso Corporation | Fluid pressure actuated poppet valve |
US9763894B2 (en) * | 2006-12-05 | 2017-09-19 | Virginia Commonwealth University | Inflammation therapy |
TW200831092A (en) * | 2006-12-21 | 2008-08-01 | Astrazeneca Ab | Therapeutic agents |
WO2008079687A1 (en) | 2006-12-22 | 2008-07-03 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands and uses thereof |
KR101222412B1 (ko) | 2007-02-15 | 2013-01-15 | 에프. 호프만-라 로슈 아게 | Taar1 리간드로서의 2-아미노옥사졸린 |
CN101765594A (zh) * | 2007-03-28 | 2010-06-30 | 雅培制药有限公司 | 作为大麻素受体配体的1,3-噻唑-2(3h)-亚基化合物 |
US7872033B2 (en) | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
US8501794B2 (en) * | 2007-04-17 | 2013-08-06 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
KR20100012031A (ko) | 2007-04-19 | 2010-02-04 | 콘서트 파마슈티컬즈, 인크. | 중수소화된 모르폴리닐 화합물 |
WO2008144360A1 (en) | 2007-05-18 | 2008-11-27 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands |
US7531685B2 (en) * | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
US8338623B2 (en) | 2007-07-09 | 2012-12-25 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
US20090088416A1 (en) * | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
US20090082471A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
WO2009045476A1 (en) | 2007-10-02 | 2009-04-09 | Concert Pharmaceuticals, Inc. | Pyrimidinedione derivatives |
US9193713B2 (en) | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US8044071B2 (en) * | 2007-10-18 | 2011-10-25 | Abbott Laboratories | Method for reducing side effects of CB2 receptor agonist therapy using a combination of a selective CB2 receptor agonist and a selective CB1 receptor antagonist |
EP2212298B1 (en) * | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
CA2703591C (en) * | 2007-10-26 | 2013-05-07 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
CA2706586A1 (en) | 2007-11-21 | 2009-05-28 | Alan S. Florjancic | Novel compounds as cannabinoid receptor ligands and uses thereof |
MX2010010023A (es) * | 2008-03-11 | 2010-11-30 | Abbott Lab | Compuestos novedosos como ligandos receptores de canabinoides. |
MX2011001755A (es) * | 2008-08-15 | 2011-03-24 | Abbott Lab | Derivados de imina como ligandos de receptor canabinoide. |
US8846730B2 (en) * | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
CN102216277A (zh) * | 2008-09-16 | 2011-10-12 | 雅培制药有限公司 | 作为大麻素受体配体的被取代的苯甲酰胺 |
CA2741047A1 (en) | 2008-11-04 | 2010-05-14 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands |
PA8854001A1 (es) | 2008-12-16 | 2010-07-27 | Abbott Lab | Compuestos novedosos como ligandos de receptores de canabinoides |
WO2010111573A1 (en) | 2009-03-27 | 2010-09-30 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
EP2411382A1 (en) * | 2009-03-27 | 2012-02-01 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
ES2542234T3 (es) | 2009-03-27 | 2015-08-03 | Abbvie Inc. | Compuestos como ligandos de receptores cannabinoides |
WO2011159785A1 (en) * | 2010-06-15 | 2011-12-22 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands |
-
2009
- 2009-09-16 CN CN2009801455637A patent/CN102216277A/zh active Pending
- 2009-09-16 EP EP15151451.0A patent/EP2896615A1/en not_active Withdrawn
- 2009-09-16 WO PCT/US2009/057088 patent/WO2010033543A2/en active Application Filing
- 2009-09-16 TW TW098131294A patent/TW201016692A/zh unknown
- 2009-09-16 AU AU2009293319A patent/AU2009293319A1/en not_active Abandoned
- 2009-09-16 PE PE2011000626A patent/PE20110804A1/es not_active Application Discontinuation
- 2009-09-16 KR KR1020117008389A patent/KR20110061619A/ko not_active Application Discontinuation
- 2009-09-16 UY UY0001032125A patent/UY32125A/es not_active Application Discontinuation
- 2009-09-16 US US12/560,897 patent/US8188135B2/en active Active
- 2009-09-16 PA PA20098842501A patent/PA8842501A1/es unknown
- 2009-09-16 BR BRPI0919135A patent/BRPI0919135A2/pt not_active IP Right Cessation
- 2009-09-16 JP JP2011527056A patent/JP2012502917A/ja active Pending
- 2009-09-16 AR ARP090103558A patent/AR073599A1/es not_active Application Discontinuation
- 2009-09-16 EP EP11192134.2A patent/EP2428507B1/en active Active
- 2009-09-16 RU RU2011115087/04A patent/RU2011115087A/ru not_active Application Discontinuation
- 2009-09-16 EP EP09792591A patent/EP2334646A2/en not_active Withdrawn
- 2009-09-16 US US12/560,893 patent/US8859596B2/en not_active Expired - Fee Related
- 2009-09-16 ES ES11192134.2T patent/ES2556752T3/es active Active
- 2009-09-16 MX MX2011002811A patent/MX2011002811A/es not_active Application Discontinuation
- 2009-09-16 CA CA2737199A patent/CA2737199A1/en not_active Abandoned
-
2010
- 2010-07-14 AR ARP100102555A patent/AR077664A2/es not_active Application Discontinuation
-
2011
- 2011-02-24 IL IL211406A patent/IL211406A0/en unknown
- 2011-03-01 ZA ZA2011/01590A patent/ZA201101590B/en unknown
- 2011-03-15 DO DO2011000081A patent/DOP2011000081A/es unknown
- 2011-03-15 CL CL2011000544A patent/CL2011000544A1/es unknown
- 2011-03-23 CO CO11035303A patent/CO6361998A2/es not_active Application Discontinuation
- 2011-04-12 EC EC2011010974A patent/ECSP11010974A/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW201016692A (en) | 2010-05-01 |
CN102216277A (zh) | 2011-10-12 |
EP2428507A2 (en) | 2012-03-14 |
WO2010033543A2 (en) | 2010-03-25 |
JP2012502917A (ja) | 2012-02-02 |
BRPI0919135A2 (pt) | 2015-12-08 |
PE20110804A1 (es) | 2011-11-30 |
EP2896615A1 (en) | 2015-07-22 |
CO6361998A2 (es) | 2012-01-20 |
EP2428507A3 (en) | 2012-06-13 |
UY32125A (es) | 2010-04-30 |
ECSP11010974A (es) | 2011-05-31 |
AR077664A2 (es) | 2011-09-14 |
CA2737199A1 (en) | 2010-03-25 |
CL2011000544A1 (es) | 2011-06-17 |
IL211406A0 (en) | 2011-05-31 |
RU2011115087A (ru) | 2012-10-27 |
ZA201101590B (en) | 2012-08-29 |
US8188135B2 (en) | 2012-05-29 |
US8859596B2 (en) | 2014-10-14 |
KR20110061619A (ko) | 2011-06-09 |
ES2556752T3 (es) | 2016-01-20 |
MX2011002811A (es) | 2011-04-12 |
DOP2011000081A (es) | 2011-07-15 |
US20100069349A1 (en) | 2010-03-18 |
EP2428507B1 (en) | 2015-10-21 |
US20100069348A1 (en) | 2010-03-18 |
PA8842501A1 (es) | 2010-04-21 |
WO2010033543A3 (en) | 2010-11-18 |
AU2009293319A1 (en) | 2010-03-25 |
EP2334646A2 (en) | 2011-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR073599A1 (es) | Compuestos heterociclicos como ligandos de receptores de canabinoides | |
AR074691A1 (es) | Derivados de tiazol como ligandos de receptores de cannabinoides | |
JP2009511490A5 (es) | ||
AR063392A1 (es) | Dihidropirazolonas sustituidas con heterociclos, procedimiento de preparacion, medicamentos que las contienen y usos en el tratamiento y/o profilaxis de enfermedades cardiovasculares,hematologicas y renales. | |
AR076170A1 (es) | Derivados heterociclicos imidazolicos y/o oxazolicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden. | |
AR096450A1 (es) | Compuestos para la modulación de quinasas, y sus indicaciones | |
AR056968A1 (es) | Compuestos espiro-oxindol y composiciones farmacéuticas | |
AR087017A1 (es) | Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos | |
DOP2010000227A (es) | Derivados biciclicos de carboxamidas aza-biciclicas, su preparacion y su aplicacion terapeutica | |
AR101986A1 (es) | Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso | |
AR098912A1 (es) | Inhibidores de syk | |
AR069083A1 (es) | Derivados heterociclicos de 1,3-tiazol inhibidores de proteinquinasas, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento o prevencion de trastornos proliferativos. | |
AR087793A1 (es) | Compuestos de benzofurano sustituido y metodos para el uso de los mismos en el tratamiento de enfermedades virales | |
AR086636A1 (es) | Ligandos sigma utiles para tratar y/o prevenir el dolor asociado a la diabetes tipo 2 y composiciones farmaceuticas que los contienen | |
AR075955A1 (es) | Utilizacion de derivados de quinazolinodiona como medicamentos para tratar y/o prevenir trastornos asociados al sistema nervioso central y/o periferico. | |
AR074130A1 (es) | Inhibidores de la diacilglicerol aciltransferasa | |
AR087984A1 (es) | Derivados biciclicos de dihidroquinolina-2-ona | |
AR074648A1 (es) | Derivados de isoxazolina que poseen un anillo de cuatro miembros como grupo terminal, intermediarios de sintesis, composiciones biocidas que los contienen y metodos para combatir y controlar dichas plagas | |
AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
AR084913A1 (es) | Derivados de aril-benzocicloalquil-amida | |
CO6260132A2 (es) | Derivados de oxadiazol como inhibidores de dgat | |
AR070655A1 (es) | Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas | |
AR082441A1 (es) | Uso de ligandos sigma en la hiperalgesia inducida por opioides | |
AR068888A1 (es) | Derivados de 1, 3, 4 - tiadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la quinesina ksp. | |
AR053342A1 (es) | Quinolonas y naftiridonas 7- maino alquilildenil- heterociclicas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |